Acumen Pharmaceuticals (ABOS) vs TuHURA Biosciences (HURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Acumen Pharmaceuticals (ABOS) has outperformed TuHURA Biosciences (HURA) over the past year, losing 16.7% versus a loss of 26.7%. Over five years, ABOS leads with a -88.2% price change compared with -99.9% for HURA. Acumen Pharmaceuticals is the larger company by market cap ($122.2 million vs $112.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | HURA |
|---|---|---|
| Share price | $1.69 | $1.76 |
| Market cap | $122.22M | $112.16M |
| 1-day change | +1.20% | -3.83% |
| YTD return | -19.91% | +132.50% |
| 1-year return | -16.75% | -26.67% |
| 5-year return | -88.25% | -99.89% |
| EPS (TTM) | $-1.64 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-121.33M | $-30.05M |
| 52-week high | $3.60 | $3.43 |
| 52-week low | $1.50 | $0.41 |
| Distance from 52-week high | -53.06% | -48.69% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +349.70% | +356.82% |
| Average volume | 439.26K | 221.74K |
| Shares outstanding | 72.32M | 63.73M |
| Employees | 60 | 22 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Healthcare · Biotechnology · 60 employees
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Healthcare · Biotechnology · 22 employees
ABOS vs HURA FAQ
Which is bigger, Acumen Pharmaceuticals or TuHURA Biosciences?
Acumen Pharmaceuticals (ABOS) is larger, with a market capitalization of $122.22M compared with $112.16M for TuHURA Biosciences (HURA).
Which stock has performed better over the past year, ABOS or HURA?
ABOS returned -16.75% over the past 12 months, compared with -26.67% for HURA (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and TuHURA Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.